This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Swedberg, K. Search for Related Content PubMed PubMed Citation Articles by Swedberg, K. Pubmed/NCBI databases Medline Plus Health Information Heart Failure Social Bookmarking                         What's this?

Conclusions on the management of heart failure

Department of Medicine, Sahlgrenska University Hospital/Ostra, Göteborg University, Gothenburg, Sweden, karl.swedberg@ hjl.gu.se

Activity of the renin-angiotensin-aldosterone system (RAAS) is increased in heart failure. Agents which act on the RAAS can be expected to benefit these patients. Recent trials which have furthered our understanding of drugs which are of benefit in heart failure — angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers and aldosterone antagonists — are discussed. It is desirable to use multiple agents for best results in patients with heart failure. New European Society of Cardiology guidelines on the management of heart failure are expected later this year.

Key Words: heart failure • aldosterone • RAAS • ACE inhibitors • ARBs • β-blockers • guidelines • myocardial infarction

References

• Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.[Free Full Text]
• Lloyd-Jones DM, Larson MG, Beiser A. et al. Lifetime risk of developing congestive heart failure. Circulation 1999;100:1-36.
• TsutsumiY, Matsubara H., Ohkubo N. et al.Angiotensin type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 1998;83:1035-46.[Abstract/Free Full Text]
• Sadoshima J., Izumo S. Molecular characterisation of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993;73:413-23.[Abstract/Free Full Text]
• SukenagaY, Kamoshita K.,Takai S., Migazaki M. Development of the chymase inhibitor as an anti-tissue remodelling drug in myocardial infarction and some other possibilities. Jpn J Pharmacol 2002;90:218-22.[CrossRef][Medline] [Order article via Infotrieve]
• Farquharson CAJ, Struthers AD Spironolactone increases nitric oxide bioavailability, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594.[Abstract/Free Full Text]
• Witherow FN, Helmy A., Webb DJ, Fox KAA, Newby DE Bradykinin contributes to the vasodilatory effects of chronic ACE inhibition in patients with heart failure. Circulation 2001;104:2177-81.[Abstract/Free Full Text]
• Granger CB, McMurray JJ, Yusuf S. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Coletta AP, Cleland JG, Freemantle N., Loh H., MemonA., Clark AL Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. Eur J Heart Fail 2003;5:697-704.[Abstract/Free Full Text]
• Dickstein K., Kjekshus J. Effect of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.[Abstract/Free Full Text]
• Cohn JN,Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.[Abstract/Free Full Text]
• McMurray JJ, Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362: 767-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Yusuf S., Pfeffer MA, Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003; 362:777-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pfeffer MA, Swedberg K., Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362: 759-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Poole-Wilson PA, Swedberg K., Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Janosi A., Ghali K., Herlitz J. et al. Metoprolol CR/XL in post-myocardial infarction patients with chronic heart failure: experience from MERIT-HF. Am Heart J 2003;146:721-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Simon T., Mary-Krause M., Funck-Brentano C., Lechat J., Jaillon P. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 2003;24:552-9.[Abstract/Free Full Text]
• Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 5, No. 1 suppl, S34-S36 (2004)
DOI: 10.3317/jraas.2004.023


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Swedberg, K. Search for Related Content PubMed PubMed Citation Articles by Swedberg, K. Pubmed/NCBI databases Medline Plus Health Information Heart Failure Social Bookmarking                         What's this?